Combining biological matrices with growth factor concentrates: toward standardized protocols in regenerative medicine [0.03%]
生物基质与生长因子浓缩物的结合：迈向再生医学的标准化方案
Eduardo Anitua,María Troya,Roberto Tierno et al.
Eduardo Anitua et al.
Introduction: Regenerative medicine offers a sophisticated array of interdependent technologies designed to restore healthy, functional tissue across diverse therapeutic scenarios. In particular, combining biologic matric...
Originator versus biosimilar adalimumab in hidradenitis suppurativa: a real-world cohort study [0.03%]
原研阿达木单抗与生物类似药阿达木单抗治疗汗腺炎的回顾性队列研究
Abdullah Demirbaş,Mustafa Esen,Esin Diremsizoğlu et al.
Abdullah Demirbaş et al.
Background and objectives: Comparative real-world data on originator and biosimilar adalimumab in hidradenitis suppurativa (HS) are limited. We compared effectiveness, persistence, and safety of originator (ADL-O) versus ...
Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study [0.03%]
一项关于生物制剂治疗银屑病患者血脂衍生的心血管风险指数12个月变化的多中心真实世界回顾性队列研究
Bahadır Aslancan,Nur Ecer,Ayşegül Tel Kankılıç et al.
Bahadır Aslancan et al.
Background: Biologic agents have transformed moderate-to-severe psoriasis treatment, but their real-world effect on lipid-derived cardiovascular risk markers remains unclear. ...
Temporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translation [0.03%]
同种异体诱导多能干细胞治疗中的时间差异：生物风险及临床转化的启示
Hiroshi Kawaguchi
Hiroshi Kawaguchi
Introduction: The clinical translation of pluripotent stem cell-derived therapies has entered a new phase following conditional approval of first-in-class allogeneic induced pluripotent stem cell (iPSC)-derived products i...
Gene therapy approaches for inborn errors of immunity: from bench to bedside [0.03%]
基因治疗在先天性免疫缺陷中的应用：从实验室到临床
Jasmeen Dara,Claire Booth
Jasmeen Dara
Introduction: Inborn errors of immunity (IEI) are rare genetic defects that disrupt immune function, often resulting in life-threatening infections, malignancies, and immune dysregulation. Allogeneic hematopoietic stem ce...
Dual REmission in moderate-to-severe AsthMa and Nasal Polyps: a multicentric observational Phase IV real-life study (DREAM-NP) [0.03%]
中重度过敏性哮喘合并鼻息肉双重维持治疗的多中心观察性IV期真实世界研究(DREAM-NP)
Francesco Menzella,Eugenio De Corso,Marco Caminati et al.
Francesco Menzella et al.
Background: Achieving simultaneous 'dual remission' in both upper and lower airways is the clinical goal for comorbid asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This multicentric observational study eva...
Breaking immune exclusion in cold tumors via TGF-β pathway inhibition [0.03%]
通过抑制TGF-β途径打破冷肿瘤中的免疫排除现象
Minjun Zhang,Yuchen Sun,Luyan Chen et al.
Minjun Zhang et al.
Ming yi , , department of breast center, the first affiliated hospital, college of medicine, zhejiang university, hangzhou, 310000, people’s republic of china introduction: Immune exclusion in cold tumors is a major mech...
Sequencing and switching among IL-17 and IL-23 biologics in plaque psoriasis: real-world lessons and precision strategies for the future [0.03%]
银屑病患者接受IL-17和IL-23生物制剂序贯或转换治疗的现实世界启示及未来精准策略
Clarissa Fava,Edoardo Zompanti,Eleonora De Luca et al.
Clarissa Fava et al.
Introduction: The therapeutic landscape of moderate-to-severe plaque psoriasis has been transformed by interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors, which offer superior effectiveness compared to older bio...
Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations [0.03%]
ANAKIRNA在秋水仙碱抵抗性的家族地中海热中的治疗实践：通过PReS AID-WP和土耳其儿科风湿病协会进行的儿科风湿病专家调查
Sıla Atamyıldız Uçar,Eray Tunce,Betül Sözeri
Sıla Atamyıldız Uçar
Background: Colchicine-resistant familial Mediterranean fever (cr-FMF) represents a therapeutic challenge, and anakinra, a recombinant interleukin-1 receptor antagonist, is widely used in clinical practice. Our aim was to...
Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer [0.03%]
基于抗体药物偶联物的非小细胞肺癌联合治疗策略进展
Yunqi Mi,Shan Wang,Yuhao Wang et al.
Yunqi Mi et al.
Introduction: Non-small cell lung cancer (NSCLC) continues to be one of the leading causes of cancer death worldwide. Although targeted therapies and immune checkpoint inhibitors have meaningfully improved outcomes for so...